IBR-733

The main study objectives are to evaluate the safety and tolerability of IBR733 cell injection in subjects with relapsed/refractory AML; to determine the recommended Phase II dose (RP2D) of IBR733 cell injection in subjects with relapsed/refractory AML. Secondary study objectives are to preliminarily evaluate the efficacy of IBR733 cell injection in subjects with relapsed/refractory AML; to characterize the pharmacokinetic (PK) characteristics of IBR733 cell injection in subjects with relapsed/refractory AML; to evaluate the immunogenicity of IBR733 cell injection in subjects with relapsed/refractory AML. Exploratory objectives are to explore the relationship between the degree of matching between human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptor (KIR) of natural killer cell (NK) donors and recipients in IBR733 and the efficacy; to retrospectively analyze the relationship between the percentage of bone marrow CD33 and C-type lectin-like molecule 1 (CLL-1) expression and the efficacy.